Valeo Pharma Inc.
VPHIF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Revenue | $53,910 | $27,745 | $13,557 | $7,470 |
| % Growth | 94.3% | 104.7% | 81.5% | – |
| Cost of Goods Sold | $40,833 | $21,464 | $9,602 | $6,089 |
| Gross Profit | $13,077 | $6,281 | $3,955 | $1,381 |
| % Margin | 24.3% | 22.6% | 29.2% | 18.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $22,562 | $18,811 | $13,306 | $3,324 |
| SG&A Expenses | $29,152 | $24,901 | $16,192 | $5,448 |
| Sales & Mktg Exp. | $6,590 | $6,090 | $2,886 | $2,124 |
| Other Operating Expenses | $1,153 | $3,221 | $456 | $276 |
| Operating Expenses | $30,305 | $28,122 | $16,648 | $5,724 |
| Operating Income | -$17,228 | -$19,604 | -$12,817 | -$4,343 |
| % Margin | -32% | -70.7% | -94.5% | -58.1% |
| Other Income/Exp. Net | -$10,580 | -$7,316 | -$1,416 | -$418 |
| Pre-Tax Income | -$27,808 | -$26,920 | -$14,233 | -$4,761 |
| Tax Expense | $0 | -$1,174 | $0 | $0 |
| Net Income | -$27,808 | -$25,746 | -$14,233 | -$4,761 |
| % Margin | -51.6% | -92.8% | -105% | -63.7% |
| EPS | -0.32 | -0.32 | -0.2 | -0.082 |
| % Growth | 0% | -60% | -143.3% | – |
| EPS Diluted | -0.32 | -0.32 | -0.2 | -0.082 |
| Weighted Avg Shares Out | 86,117 | 80,859 | 69,930 | 57,909 |
| Weighted Avg Shares Out Dil | 86,117 | 80,859 | 69,930 | 57,909 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,722 | $173 | $1 | $1 |
| Interest Expense | $13,790 | $6,461 | $1,356 | $598 |
| Depreciation & Amortization | $2,626 | $1,047 | $407 | $424 |
| EBITDA | -$11,392 | -$16,100 | -$10,975 | -$3,739 |
| % Margin | -21.1% | -58% | -81% | -50.1% |